Market Closed -
Nasdaq
01:30:00 01/05/2024 am IST
|
5-day change
|
1st Jan Change
|
2.22
USD
|
+6.73%
|
|
-2.20%
|
-43.65%
|
Fiscal Period: December |
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
807.7
|
163.5
|
433.9
|
264.7
|
-
|
-
|
Enterprise Value (EV)
1 |
216.3
|
-208.5
|
233.2
|
100.6
|
39.64
|
-37.44
|
P/E ratio
|
-1.36
x
|
-0.67
x
|
-2.18
x
|
-2.22
x
|
-4.63
x
|
-17.1
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
-
|
1.5
x
|
0.81
x
|
0.56
x
|
EV / Revenue
|
-
|
-
|
-
|
0.57
x
|
0.12
x
|
-0.08
x
|
EV / EBITDA
|
-0.95
x
|
0.9
x
|
-1.1
x
|
-1.19
x
|
-1.68
x
|
-1.19
x
|
EV / FCF
|
-
|
-
|
-1.34
x
|
-0.63
x
|
-0.34
x
|
1.99
x
|
FCF Yield
|
-
|
-
|
-74.5%
|
-158%
|
-297%
|
50.2%
|
Price to Book
|
1.45
x
|
0.46
x
|
2.45
x
|
1.75
x
|
1.21
x
|
0.9
x
|
Nbr of stocks (in thousands)
|
1,11,252
|
1,08,982
|
1,10,115
|
1,19,221
|
-
|
-
|
Reference price
2 |
7.260
|
1.500
|
3.940
|
2.220
|
2.220
|
2.220
|
Announcement Date
|
30/03/22
|
23/03/23
|
28/03/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
-
|
-
|
176.4
|
325.6
|
474.6
|
EBITDA
1 |
-226.9
|
-230.6
|
-212.3
|
-84.43
|
-23.54
|
31.49
|
EBIT
1 |
-226.9
|
-230.7
|
-212.8
|
-135.7
|
-72.2
|
3.75
|
Operating Margin
|
-
|
-
|
-
|
-76.92%
|
-22.18%
|
0.79%
|
Earnings before Tax (EBT)
1 |
-226.8
|
-241.3
|
-198.6
|
-136.4
|
-61.1
|
-17.5
|
Net income
1 |
-226.8
|
-241.3
|
-198.6
|
-136.4
|
-61.1
|
-17.5
|
Net margin
|
-
|
-
|
-
|
-77.28%
|
-18.77%
|
-3.69%
|
EPS
2 |
-5.320
|
-2.230
|
-1.810
|
-1.000
|
-0.4800
|
-0.1300
|
Free Cash Flow
1 |
-
|
-
|
-173.8
|
-159.2
|
-117.6
|
-18.8
|
FCF margin
|
-
|
-
|
-
|
-90.24%
|
-36.12%
|
-3.96%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
30/03/22
|
23/03/23
|
28/03/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
6
|
45.13
|
113.3
|
92
|
EBITDA
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-38.95
|
-53.75
|
-42.94
|
-76.63
|
-52.7
|
-47.4
|
-44.4
|
6.2
|
-
|
EBIT
1 |
-60.42
|
-83.09
|
-100.7
|
-51.75
|
-47.33
|
-48.21
|
-39.07
|
-53.88
|
-43.06
|
-76.75
|
-57.63
|
-54.83
|
-33.33
|
9.8
|
-35.6
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-913.89%
|
-73.86%
|
8.65%
|
-38.7%
|
Earnings before Tax (EBT)
1 |
-60.38
|
-83.04
|
-100.7
|
-50.99
|
-45.09
|
-44.57
|
-35.32
|
-50.23
|
-39.44
|
-73.65
|
-60.9
|
-52.8
|
-25.95
|
2.25
|
-32.5
|
Net income
1 |
-60.38
|
-83.04
|
-100.7
|
-50.99
|
-45.09
|
-44.57
|
-35.32
|
-50.23
|
-39.44
|
-73.65
|
-60.9
|
-52.8
|
-25.95
|
2.25
|
-32.5
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-880%
|
-57.5%
|
1.99%
|
-35.33%
|
EPS
2 |
-0.9800
|
-0.7600
|
-0.9300
|
-0.4700
|
-0.4200
|
-0.4100
|
-0.3200
|
-0.4600
|
-0.3600
|
-0.6700
|
-0.5050
|
-0.4100
|
-0.2050
|
0.0200
|
-0.0700
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
15/11/21
|
30/03/22
|
13/05/22
|
15/08/22
|
10/11/22
|
23/03/23
|
11/05/23
|
10/08/23
|
09/11/23
|
28/03/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
591
|
372
|
201
|
164
|
225
|
302
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-
|
-174
|
-159
|
-118
|
-18.8
|
ROE (net income / shareholders' equity)
|
-81.8%
|
-52.8%
|
-74.5%
|
-17.8%
|
39%
|
32.3%
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
2 |
5.020
|
3.260
|
1.610
|
1.270
|
1.830
|
2.480
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
-
|
-
|
0.62
|
10.8
|
11.8
|
12.8
|
Capex / Sales
|
-
|
-
|
-
|
6.12%
|
3.62%
|
2.7%
|
Announcement Date
|
30/03/22
|
23/03/23
|
28/03/24
|
-
|
-
|
-
|
Last Close Price
2.22
USD Average target price
9.375
USD Spread / Average Target +322.30% Consensus |
1st Jan change
|
Capi.
|
---|
| -43.65% | 248M | | -3.46% | 102B | | +1.41% | 96.29B | | +2.13% | 22.18B | | -15.84% | 21.2B | | -9.21% | 18.31B | | -39.98% | 17.38B | | -14.65% | 16.36B | | +4.39% | 13.97B | | +31.35% | 12.17B |
Bio Therapeutic Drugs
|